目的　探讨新型疫苗主动治疗急性白血病及多发性骨髓瘤的疗效及毒副作用。方法　应用基因工程生产的细胞因子和急性白血病及多发性骨髓瘤肿瘤细胞制备的疫苗 ,主动免疫治疗急性白血病 7例、多发性骨髓瘤37例。结果　 37例急性白血病患者中化疗未缓解或化疗不能耐受者 2 9例 ,经疫苗治疗达到完全缓解者 5例占17.3% ,部分缓解者 6例占 2 0 .7% ,微效者 4例占 13.8%。总有效率 5 1.8%。化疗缓解组 8例疫苗治疗后维持缓解达 8～ 13个月复发。多发性骨髓瘤 7例 ,其中 1例完全缓解 ,5例部分缓解。治疗中未发现明显副作用。结论　应用新型疫苗治疗化疗无效或化疗不能耐受的急性白血病及多发性骨髓瘤具有肯定疗效。且经济简便 ,无明显毒副作用 Objective To investigate the curative effect and toxicity of active vaccine against acute leukemia and multiple myeloma. Methods The vaccine produced by genetically engineered cytokines and acute leukemia and multiple myeloma tumor cells was used in active immunotherapy of acute leukemia in 7 cases and multiple myeloma in 37 cases. Results Among the 37 patients with acute leukemia, 29 cases were not relieved of chemotherapy or chemotherapy can not tolerate, 5 cases accounted for 17.3% of the complete remission after treatment with vaccine, 6 cases of partial remission were 20.7% and 4 cases of low efficiency Accounting for 13.8%. The total effective rate of 5 1.8%. In the chemotherapy remission group, eight patients remained eased for 8 to 13 months after treatment. Seven cases of multiple myeloma, including 1 complete remission, 5 patients partially relieved. No obvious side effects were found during treatment. Conclusion The application of the new vaccine in the treatment of ineffective chemotherapy or chemotherapy can not tolerate acute leukemia and multiple myeloma with a positive effect. And the economy is simple, no obvious side effects